08-02-2022
askarim / Shutterstock.com
AstraZeneca and Merck, Sharp & Dohme (MSD) have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence (acalabrutinib) infringe six patents.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
AstraZeneca, MSD, MSN, Sandoz, Calquence, US District Court for the District of Delaware, generics
MSD prevails in diabetes drug dispute with Mylan
29-09-2022
MSD targets Mankind’s diabetes generic in patent suit
05-04-2022
MSD, Pfizer try to stop three Steglatro generics
29-03-2022
Ono sues AstraZeneca over antibody patents
01-03-2022
Judge partially revives California pay-for-delay ban
17-02-2022
AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler
27-01-2022
AstraZeneca inks $730m licensing deal for rare heart disease treatment
11-01-2022
